Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The article contrasts Amgen’s stability with Axsome’s faster growth: Amgen posted FY2025 free cash flow of ~$8.1B and FY2025 revenue near ~$36.7B (+~9.9% YoY) versus Axsome’s FY2025 revenue of ~$638.5M (+65.5% YoY) but net loss of ~$183.2M and negative free cash flow of ~$93.9M. Valuation also diverges, with Amgen trading at a forward P/E of 19.1 and P/S of 6.5 versus Axsome’s forward P/E of 44.5 and P/S of 16.7. Overall, it frames Amgen as lower-risk and cash-generative (including a dividend) while Axsome is higher-risk with more upside but priced for continued success.

Analysis

Amgen is the cleaner cash-generation asset, but the market is likely underappreciating how much of its risk is already visible and financeable: payer pressure, legal noise, and customer concentration are all slow-moving headwinds that typically compress multiples, not destroy the franchise. The more important second-order effect is that its scale and free cash flow make it a durable capital-return machine, which tends to support downside in weak tape and makes it a relative defensive within large-cap biotech versus higher-beta peers.

Axsome’s growth profile is attractive, but the equity is functioning more like a long-duration asset: any slowdown in prescription momentum, reimbursement friction, or trial slippage can hit valuation before the P&L is fully visible. That makes the stock highly sensitive to the next 1-3 earnings prints and any financing/partnering headlines; if commercial adoption keeps compounding, the multiple can stay elevated, but if growth decelerates even modestly, the market will likely de-rate it faster than consensus expects.

The contrarian view is that the valuation gap may already be enough to compensate for AXSM’s execution risk, while AMGN’s debt optics are less important than its interest coverage and FCF conversion. In other words, this is less about “cheap vs expensive” and more about “observable cash today vs probability-weighted cash later,” with the market likely overpaying for visible growth and underpaying for cash durability. Watch for any guidance revision, reimbursement commentary, or a sharp change in biotech risk appetite as the main falsifiers over the next quarter.

Key Decisions for Investors

• Prefer AMGN as the lower-volatility biotech anchor over a 3-6 month horizon; use it as a defensive substitute for more crowded pharma income names if the goal is cash yield plus buyback support.
• If taking relative value risk, favor long AMGN / short AXSM into the next earnings cycle: the pair expresses cash-flow durability vs. growth-multiple fragility, with better risk control than a naked long in either name.
• For AXSM, wait for post-earnings confirmation before adding exposure; if revenue growth decelerates meaningfully or management raises spend without clear commercial acceleration, expect multiple compression to be the first reaction.
• Set a watch item on MCK/COR/CAH margins and AMGN channel mix: any distributor margin squeeze or customer renegotiation would be the fastest way for AMGN’s top-line stability thesis to weaken.
• If AXSM continues compounding without a financing need, consider upside optionality only after the market proves durability; otherwise the current setup is more suitable for a tactical trade than a core long.